Event | Toripalimab plus IMRT N=25 | ||||
All grades | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | |
Acute toxicity | Number of patients with event (%) | ||||
Thrombocytopenia | 1 (4.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Neutropenia | 2 (8.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Leukopenia | 4 (16.0) | 4 (16.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
ALT elevation | 5 (20.0) | 5 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
AST elevation | 3 (12.0) | 3 (12.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Total bilirubin elevation | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Direct bilirubin elevation | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Blood cholesterol elevation | 6 (24.0) | 6 (24.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Blood triglyceride elevation | 12 (48.0) | 11 (44.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) |
Hyperglycemia | 9 (36.0) | 9 (36.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Serum creatinine elevation | 13 (52.0) | 13 (52.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Creatine kinase elevation | 5 (20.0) | 4 (16.0) | 0 (0.0) | 1 (4.0) | 0 (0.0) |
Hypertension | 3 (12.0) | 3 (12.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Hypothyroidism | 8 (32.0) | 8 (32.0) | 0 (0.0) | 0 (0.0) | 0 (0.0 |
Hyperthyroidism | 1 (4.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Nausea | 19 (76.0) | 19 (76.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Vomiting | 2 (8.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Diarrhea | 1 (4.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Pruritus | 8 (32.0) | 8 (32.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Capillary hyperplasia | 1 (4.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Fever | 1 (4.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Weight loss | 11 (44.0) | 11 (44.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Fatigue | 22 (88.0) | 22 (88.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Myositis or myalgia | 4 (16.0) | 4 (16.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Joint pain | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Pneumonia | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Infusion reaction | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Skin reaction | 10 (40.0) | 8 (32.0) | 2 (8.0) | 0 (0.0) | 0 (0.0) |
Mucositis | 23 (92.0) | 22 (88.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) |
Dry mouth | 24 (96.0) | 24 (96.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Late toxicity | |||||
Nasopharyngeal wall necrosis | 11 (44.0) | 4 (16.0) | 3 (12.0) | 4 (16.0) | 0 (0.0) |
Massive nasal bleeding | 3 (12.0) | 0 (0.0) | 0 (0.0) | 2 (8.0) | 1 (4.0) |
Eye damage | 9 (36.0) | 9 (36.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Deafness | 18 (72.0) | 18 (72.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Trismus | 10 (40.0) | 9 (36.0) | 1 (4.0) | 0 (0.0) | 0 (0.0) |
Dry mouth | 18 (72.0) | 18 (72.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Skin reaction | 4 (16.0) | 4 (16.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Neck tissue damage | 7 (28.0) | 7 (28.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Cranial neuropathy | 9 (36.0) | 9 (36.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
All data are presented as No. (%).
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; IMRT, intensity-modulated radiotherapy .